There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide,
leading to approximately 170,000 deaths. Renal cell carcinoma (RCC) accounts for more …

Background Systemic therapy (ST) can be deferred in patients who have metastatic renal
cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients …

Purpose: The optimal sequence of cytoreductive nephrectomy and targeted therapy of
metastatic renal cell carcinoma is unclear. We compared overall survival between patients …

The treatment of renal cell carcinoma represents one of the great success stories in
translational cancer research, with the development of novel therapies targeting key …

Apigenin is a flavonoid widely presented in fruits and vegetables, and is known to possess
anti‑inflammatory, antioxidant, and anticancer properties. The present study was designed to …

Clear cell renal cell carcinoma (ccRCC), accounting for 70–80% of all renal cell carcinomas,
is a common malignancy. Survival rates decrease significantly in patients with advanced …

Background Active surveillance (AS) is a commonly used strategy in patients with slow-
growing disease. We aimed to assess the outcomes and safety of AS in patients with …

A subset of patients with metastatic renal cell carcinoma (mRCC) follow an indolent disease
course and may benefit from initial active surveillance (AS). However, selecting patients …

Metastasis therapies for renal cancer : Current Opinion in Urology Metastasis therapies for
renal cancer : Current Opinion in Urology Log in or Register Subscribe to journalSubscribe Get …